The DOI matches its Crossref record; 195 of the 195 references it cites were found in a registry or an index.
Interferon-γ: teammate or opponent in the tumour microenvironment?
Open accessAbstract
Cancer immunotherapy offers substantive benefit to patients with various tumour types, in some cases leading to complete tumour clearance. However, many patients do not respond to immunotherapy, galvanizing the field to define the mechanisms of pre-existing and acquired resistance. Interferon-γ (IFNγ) is a cytokine that has both protumour and antitumour activities, suggesting that it may serve as a nexus for responsiveness to immunotherapy. Many cancer immunotherapies and chemotherapies induce IFNγ production by various cell types, including activated T cells and natural killer cells. Patients resistant to these therapies commonly have molecular aberrations in the IFNγ signalling pathway or express resistance molecules driven by IFNγ. Given that all nucleated cells can respond to IFNγ, the functional consequences of IFNγ production need to be carefully dissected on a cell-by-cell basis. Here, we review the cells that produce IFNγ and the different effects of IFNγ in the tumour microenvironment, highlighting the pleiotropic nature of this multifunctional and abundant cytokine. Vignali and colleagues discuss the pleiotropic roles of interferon-γ (IFNγ) in the tumour microenvironment; on the one hand, it acts as a ‘teammate’ to promote antitumour immune responses and, on the other hand, it acts as an ‘opponent’ promoting tumour growth and suppressing immune responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Vignali, D. A. A., Collison, L. W., & Workman, C. J. (2008) · Nature Reviews Immunology · doi:10.1038/nri2343 · Cited by 3,463
Self-citationMutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
The prognostic landscape of genes and infiltrating immune cells across human cancers
Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3909 · Cited by 3,118
CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy
Wang, W., Green, M., Choi, J. E., Gijón, M., Kennedy, P. D., Johnson, J. K., Liao, P., Lang, X., Kryczek, I., Sell, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1170-y · Cited by 2,880
Cloning of a new cytokine that induces IFN-γ production by T cells
Okamura, H., Tsutsui, H., Komatsu, T., Yutsudo, M., Hakura, A., Tanimoto, T., Torigoe, K., Okura, T., Nukada, Y., Hattori, K., et al. (1995) · Nature · doi:10.1038/378088a0 · Cited by 2,600
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Kawai, T., & Akira, S. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401850 · Cited by 1,810
MAP Kinases in the Immune Response
Dong, C., Davis, R. J., & Flavell, R. A. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.091301.131133 · Cited by 1,662
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy
Tokunaga, R., Zhang, W., Naseem, M., Puccini, A., Berger, M. D., Soni, S., McSkane, M., Baba, H., & Lenz, H.-J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.007 · Cited by 1,627
The Molecular Cell Biology of Interferon-gamma and its Receptor
Farrar, M. A., & Schreiber, R. D. (1993) · Annual Review of Immunology · doi:10.1146/annurev.iy.11.040193.003035 · Cited by 1,341
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300
IL-12 family cytokines: immunological playmakers
Vignali, D. A. A., & Kuchroo, V. K. (2012) · Nature Immunology · doi:10.1038/ni.2366 · Cited by 1,297
Self-citationKoch, M. A., Tucker-Heard, G., Perdue, N. R., Killebrew, J. R., Urdahl, K. B., & Campbell, D. J. (2009) · Nature Immunology · doi:10.1038/ni.1731 · Cited by 1,258
The Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis
Strieter, R. M., Polverini, P. J., Kunkel, S. L., Arenberg, D. A., Burdick, M. D., Kasper, J., Dzuiba, J., Van Damme, J., Walz, A., Marriott, D., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.27348 · Cited by 1,222
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.022 · Cited by 1,216
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201
Distinct Effects of T-bet in T H 1 Lineage Commitment and IFN-γ Production in CD4 and CD8 T Cells
Szabo, S. J., Sullivan, B. M., Stemmann, C., Satoskar, A. R., Sleckman, B. P., & Glimcher, L. H. (2002) · Science · doi:10.1126/science.1065543 · Cited by 1,172
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau-Guilemond, J., Valsesia-Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,108
Rodell, C. B., Arlauckas, S. P., Cuccarese, M. F., Garris, C. S., Li, R., Ahmed, M. S., Kohler, R. H., Pittet, M. J., & Weissleder, R. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0236-8 · Cited by 1,099
T cell apoptosis by tryptophan catabolism
Fallarino, F., Grohmann, U., Vacca, C., Bianchi, R., Orabona, C., Spreca, A., Fioretti, M. C., & Puccetti, P. (2002) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401073 · Cited by 1,022
Control of Effector CD8 + T Cell Function by the Transcription Factor Eomesodermin
Pearce, E. L., Mullen, A. C., Martins, G. A., Krawczyk, C. M., Hutchins, A. S., Zediak, V. P., Banica, M., DiCioccio, C. B., Gross, D. A., Mao, C.-A., et al. (2003) · Science · doi:10.1126/science.1090148 · Cited by 1,014
Regulation of Cutaneous Malignancy by γδ T Cells
Girardi, M., Oppenheim, D. E., Steele, C. R., Lewis, J. M., Glusac, E., Filler, R., Hobby, P., Sutton, B., Tigelaar, R. E., & Hayday, A. C. (2001) · Science · doi:10.1126/science.1063916 · Cited by 1,004
Garris, C. S., Arlauckas, S. P., Kohler, R. H., Trefny, M. P., Garren, S., Piot, C., Engblom, C., Pfirschke, C., Siwicki, M., Gungabeesoon, J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.024 · Cited by 966
Monaco, G., Lee, B., Xu, W., Mustafah, S., Hwang, Y. Y., Carré, C., Burdin, N., Visan, L., Ceccarelli, M., Poidinger, M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.041 · Cited by 958
Regulation of MHC Class II Expression by Interferon-γ Mediated by the Transactivator Gene CIITA
Steimle, V., Siegrist, C.-A., Mottet, A., Lisowska-Grospierre, B., & Mach, B. (1994) · Science · doi:10.1126/science.8016643 · Cited by 898
Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression
Schmiedel, B. J., Singh, D., Madrigal, A., Valdovino-Gonzalez, A. G., White, B. M., Zapardiel-Gonzalo, J., Ha, B., Altay, G., Greenbaum, J. A., McVicker, G., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.022 · Cited by 867
Carnaud, C., Lee, D., Donnars, O., Park, S.-H., Beavis, A., Koezuka, Y., & Bendelac, A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.9.4647 · Cited by 854
Kryczek, I., Banerjee, M., Cheng, P., Vatan, L., Szeliga, W., Wei, S., Huang, E., Finlayson, E., Simeone, D., Welling, T. H., et al. (2009) · Blood · doi:10.1182/blood-2009-03-208249 · Cited by 813
Recombinant IL-12 administration induces tumor regression in association with IFN- gamma production.
Nastala, C. L., Edington, H. D., McKinney, T. G., Tahara, H., Nalesnik, M. A., Brunda, M. J., Gately, M. K., Wolf, S. F., Schreiber, R. D., Storkus, W. J., et al. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.4.1697 · Cited by 780
Nuclear Export of NF-ATc Enhanced by Glycogen Synthase Kinase-3
Beals, C. R., Sheridan, C. M., Turck, C. W., Gardner, P., & Crabtree, G. R. (1997) · Science · doi:10.1126/science.275.5308.1930 · Cited by 754
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Maude, S. L., Teachey, D. T., Porter, D. L., & Grupp, S. A. (2015) · Blood · doi:10.1182/blood-2014-12-580068 · Cited by 727
Interferon-Like Virus-Inhibitor Induced in Human Leukocytes by Phytohemagglutinin
Wheelock, E. F. (1965) · Science · doi:10.1126/science.149.3681.310 · Cited by 725
Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691
Turning the corner on therapeutic cancer vaccines
Hollingsworth, R. E., & Jansen, K. (2019) · npj Vaccines · doi:10.1038/s41541-019-0103-y · Cited by 689
The Interaction Properties of Costimulatory Molecules Revisited
Collins, A. V., Brodie, D. W., Gilbert, R. J. C., Iaboni, A., Manso-Sancho, R., Walse, B., Stuart, D. I., van der Merwe, P. A., & Davis, S. J. (2002) · Immunity · doi:10.1016/s1074-7613(02)00362-x · Cited by 684
Mechanism of CD1d-restricted natural killer T cell activation during microbial infection
Brigl, M., Bry, L., Kent, S. C., Gumperz, J. E., & Brenner, M. B. (2003) · Nature Immunology · doi:10.1038/ni1002 · Cited by 672
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
Cillo, A. R., Kürten, C. H. L., Tabib, T., Qi, Z., Onkar, S., Wang, T., Liu, A., Duvvuri, U., Kim, S., Soose, R. J., et al. (2020) · Immunity · doi:10.1016/j.immuni.2019.11.014 · Cited by 668
Self-citationDighe, A. S., Richards, E., Old, L. J., & Schreiber, R. D. (1994) · Immunity · doi:10.1016/1074-7613(94)90087-6 · Cited by 663
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity
Overacre-Delgoffe, A. E., Chikina, M., Dadey, R. E., Yano, H., Brunazzi, E. A., Shayan, G., Horne, W., Moskovitz, J. M., Kolls, J. K., Sander, C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.005 · Cited by 627
Self-citationGomez, J. A., Wapinski, O. L., Yang, Y. W., Bureau, J.-F., Gopinath, S., Monack, D. M., Chang, H. Y., Brahic, M., & Kirkegaard, K. (2013) · Cell · doi:10.1016/j.cell.2013.01.015 · Cited by 627
Discovery of IDO1 Inhibitors: From Bench to Bedside
Prendergast, G. C., Malachowski, W. P., DuHadaway, J. B., & Muller, A. J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2285 · Cited by 558
Benci, J. L., Johnson, L. R., Choa, R., Xu, Y., Qiu, J., Zhou, Z., Xu, B., Ye, D., Nathanson, K. L., June, C. H., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.019 · Cited by 541
Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
Benmebarek, M.-R., Karches, C. H., Cadilha, B. L., Lesch, S., Endres, S., & Kobold, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061283 · Cited by 531
The dual role of iNOS in cancer
Vannini, F., Kashfi, K., & Nath, N. (2015) · Redox Biology · doi:10.1016/j.redox.2015.08.009 · Cited by 524
T Helper Cell Fate Specified by Kinase-Mediated Interaction of T-bet with GATA-3
Hwang, E. S., Szabo, S. J., Schwartzberg, P. L., & Glimcher, L. H. (2005) · Science · doi:10.1126/science.1103336 · Cited by 519
Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity
Bhat, P., Leggatt, G., Waterhouse, N., & Frazer, I. H. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.67 · Cited by 515
Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment
Teleanu, R. I., Chircov, C., Grumezescu, A. M., & Teleanu, D. M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010084 · Cited by 503
Interleukin 2-mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets.
Kasahara, T., Hooks, J. J., Dougherty, S. F., & Oppenheim, J. J. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.130.4.1784 · Cited by 479
Villegas, F. R., Coca, S., Villarrubia, V. G., Jiménez, R., Chillón, M. J., Jareño, J., Zuil, M., & Callol, L. (2002) · Lung Cancer · doi:10.1016/s0169-5002(01)00292-6 · Cited by 467
The molecular basis of JAK/STAT inhibition by SOCS1
Liau, N. P. D., Laktyushin, A., Lucet, I. S., Murphy, J. M., Yao, S., Whitlock, E., Callaghan, K., Nicola, N. A., Kershaw, N. J., & Babon, J. J. (2018) · Nature Communications · doi:10.1038/s41467-018-04013-1 · Cited by 456
γδ T Cells Provide an Early Source of Interferon γ in Tumor Immunity
Gao, Y., Yang, W., Pan, M., Scully, E., Girardi, M., Augenlicht, L. H., Craft, J., & Yin, Z. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030584 · Cited by 453
NLR family member NLRC5 is a transcriptional regulator of MHC class I genes
Meissner, T. B., Li, A., Biswas, A., Lee, K.-H., Liu, Y.-J., Bayir, E., Iliopoulos, D., van den Elsen, P. J., & Kobayashi, K. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008684107 · Cited by 447
Targeting the IDO1 pathway in cancer: from bench to bedside
Liu, M., Wang, X., Wang, L., Ma, X., Gong, Z., Zhang, S., & Li, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0644-y · Cited by 447
GAS Elements: A Few Nucleotides with a Major Impact on Cytokine-Induced Gene Expression
DECKER, T., KOVARIK, P., & MEINKE, A. (1997) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1997.17.121 · Cited by 437
IDO1 in cancer: a Gemini of immune checkpoints
Zhai, L., Ladomersky, E., Lenzen, A., Nguyen, B., Patel, R., Lauing, K. L., Wu, M., & Wainwright, D. A. (2018) · Cellular & Molecular Immunology · doi:10.1038/cmi.2017.143 · Cited by 437
T cells use two directionally distinct pathways for cytokine secretion
Huse, M., Lillemeier, B. F., Kuhns, M. S., Chen, D. S., & Davis, M. M. (2006) · Nature Immunology · doi:10.1038/ni1304 · Cited by 436
Three-dimensional structure of recombinant human interferon-gamma
Ealick, S., Cook, W., Vijay-Kumar, S., Carson, M., Nagabhushan, T., Trotta, P., & Bugg, C. (1991) · Science · doi:10.1126/science.1902591 · Cited by 426
Myeloid Cell-Derived Arginase in Cancer Immune Response
Grzywa, T. M., Sosnowska, A., Matryba, P., Rydzynska, Z., Jasinski, M., Nowis, D., & Golab, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00938 · Cited by 424
Gubin, M. M., Esaulova, E., Ward, J. P., Malkova, O. N., Runci, D., Wong, P., Noguchi, T., Arthur, C. D., Meng, W., Alspach, E., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.030 · Cited by 419
Interferon γ Is Required for Activation-induced Death of T Lymphocytes
Refaeli, Y., Van Parijs, L., Alexander, S. I., & Abbas, A. K. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020666 · Cited by 417
Novel Foxo1-dependent transcriptional programs control Treg cell function
Ouyang, W., Liao, W., Luo, C. T., Yin, N., Huse, M., Kim, M. V., Peng, M., Chan, P., Ma, Q., Mo, Y., et al. (2012) · Nature · doi:10.1038/nature11581 · Cited by 413
Stability and function of regulatory T cells expressing the transcription factor T-bet
Levine, A. G., Mendoza, A., Hemmers, S., Moltedo, B., Niec, R. E., Schizas, M., Hoyos, B. E., Putintseva, E. V., Chaudhry, A., Dikiy, S., et al. (2017) · Nature · doi:10.1038/nature22360 · Cited by 393
Diskin, B., Adam, S., Cassini, M. F., Sanchez, G., Liria, M., Aykut, B., Buttar, C., Li, E., Sundberg, B., Salas, R. D., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0620-x · Cited by 392
Mitchell, T. C., Hamid, O., Smith, D. C., Bauer, T. M., Wasser, J. S., Olszanski, A. J., Luke, J. J., Balmanoukian, A. S., Schmidt, E. V., Zhao, Y., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9602 · Cited by 388
Lazarevic, V., Chen, X., Shim, J.-H., Hwang, E.-S., Jang, E., Bolm, A. N., Oukka, M., Kuchroo, V. K., & Glimcher, L. H. (2011) · Nature Immunology · doi:10.1038/ni.1969 · Cited by 385
Natural Killer Cell Accumulation in Tumors Is Dependent on IFN-γ and CXCR3 Ligands
Wendel, M., Galani, I. E., Suri-Payer, E., & Cerwenka, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1440 · Cited by 378
MicroRNA-29 Regulates T-Box Transcription Factors and Interferon-γ Production in Helper T Cells
Steiner, D. F., Thomas, M. F., Hu, J. K., Yang, Z., Babiarz, J. E., Allen, C. D. C., Matloubian, M., Blelloch, R., & Ansel, K. M. (2011) · Immunity · doi:10.1016/j.immuni.2011.07.009 · Cited by 365
Interferon gamma in cancer immunotherapy
Ni, L., & Lu, J. (2018) · Cancer Medicine · doi:10.1002/cam4.1700 · Cited by 360
Yan, Y., Zhang, G.-X., Gran, B., Fallarino, F., Yu, S., Li, H., Cullimore, M. L., Rostami, A., & Xu, H. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001628 · Cited by 358
Liu, C., Chikina, M., Deshpande, R., Menk, A. V., Wang, T., Tabib, T., Brunazzi, E. A., Vignali, K. M., Sun, M., Stolz, D. B., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.017 · Cited by 345
Self-citationCytokine-mediated communication: a quantitative appraisal of immune complexity
Altan-Bonnet, G., & Mukherjee, R. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0131-x · Cited by 341
Fields, P. E., Kim, S. T., & Flavell, R. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.2.647 · Cited by 328
CD8+ T cell contraction is controlled by early inflammation
Badovinac, V. P., Porter, B. B., & Harty, J. T. (2004) · Nature Immunology · doi:10.1038/ni1098 · Cited by 320
Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer
Haabeth, O. A. W., Lorvik, K. B., Hammarström, C., Donaldson, I. M., Haraldsen, G., Bogen, B., & Corthay, A. (2011) · Nature Communications · doi:10.1038/ncomms1239 · Cited by 318
TLR7/8-Mediated Activation of Human NK Cells Results in Accessory Cell-Dependent IFN-γ Production
Hart, O. M., Athie-Morales, V., O’Connor, G. M., & Gardiner, C. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1636 · Cited by 310
Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma
Gleave, M. E., Elhilali, M., Fradet, Y., Davis, I., Venner, P., Saad, F., Klotz, L. H., Moore, M. J., Paton, V., Bajamonde, A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804303381804 · Cited by 308
Ouyang, W., Beckett, O., Flavell, R. A., & Li, M. O. (2009) · Immunity · doi:10.1016/j.immuni.2009.02.003 · Cited by 306
Greenlund, A. C., Morales, M. O., Viviano, B. L., Yan, H., Krolewski, J., & Schreiber, R. D. (1995) · Immunity · doi:10.1016/1074-7613(95)90012-8 · Cited by 304
Antigen presentation by MHC class I and its regulation by interferon γ
Früh, K., & Yang, Y. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)80014-4 · Cited by 297
IFNγ signaling—Does it mean JAK–STAT?
Gough, D. J., Levy, D. E., Johnstone, R. W., & Clarke, C. J. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.08.004 · Cited by 289
Lack of Interferon γ Receptor β Chain and the Prevention of Interferon γ Signaling in T H 1 Cells
Pernis, A., Gupta, S., Gollob, K. J., Garfein, E., Coffman, R. L., Schindler, C., & Rothman, P. (1995) · Science · doi:10.1126/science.7618088 · Cited by 285
Xu, X., Fu, X.-Y., PLATE, J. M. D., & Chong, A. S. (1998) · PubMed · Cited by 283
Human T H 17 Cells Are Long-Lived Effector Memory Cells
Kryczek, I., Zhao, E., Liu, Y., Wang, Y., Vatan, L., Szeliga, W., Moyer, J., Klimczak, A., Lange, A., & Zou, W. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002949 · Cited by 278
Intracellular Domains of CXCR3 That Mediate CXCL9, CXCL10, and CXCL11 Function
Colvin, R. A., Campanella, G. S. V., Sun, J., & Luster, A. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403595200 · Cited by 274
INTERFEROME: the database of interferon regulated genes
Samarajiwa, S. A., Forster, S., Auchettl, K., & Hertzog, P. J. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn732 · Cited by 265
Nakahira, M., Ahn, H.-J., Park, W.-R., Gao, P., Tomura, M., Park, C.-S., Hamaoka, T., Ohta, T., Kurimoto, M., & Fujiwara, H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.3.1146 · Cited by 261
Wagner, T. L., Ahonen, C. L., Couture, A. M., Gibson, S. J., Miller, R. L., Smith, R. M., Reiter, M. J., Vasilakos, J. P., & Tomai, M. A. (1999) · Cellular Immunology · doi:10.1006/cimm.1998.1406 · Cited by 258
Koch, M. A., Thomas, K. R., Perdue, N. R., Smigiel, K. S., Srivastava, S., & Campbell, D. J. (2012) · Immunity · doi:10.1016/j.immuni.2012.05.031 · Cited by 253
Stat1-independent regulation of gene expression in response to IFN-γ
Ramana, C. V., Gil, M. P., Han, Y., Ransohoff, R. M., Schreiber, R. D., & Stark, G. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111164198 · Cited by 243
Toll-Like Receptor Ligands and Interferon-γ Synergize for Induction of Antitumor M1 Macrophages
Müller, E., Christopoulos, P. F., Halder, S., Lunde, A., Beraki, K., Speth, M., Øynebråten, I., & Corthay, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01383 · Cited by 239
Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
Chen, F., Zou, Z., Du, J., Su, S., Shao, J., Meng, F., Yang, J., Xu, Q., Ding, N., Yang, Y., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci99538 · Cited by 229
T Lymphocytes Negatively Regulate Lymph Node Lymphatic Vessel Formation
Kataru, R. P., Kim, H., Jang, C., Choi, D. K., Koh, B. I., Kim, M., Gollamudi, S., Kim, Y.-K., Lee, S.-H., & Koh, G. Y. (2011) · Immunity · doi:10.1016/j.immuni.2010.12.016 · Cited by 226
Jackson, S. W., Jacobs, H. M., Arkatkar, T., Dam, E. M., Scharping, N. E., Kolhatkar, N. S., Hou, B., Buckner, J. H., & Rawlings, D. J. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151724 · Cited by 207
Diverse roles of miR-29 in cancer (Review)
JIANG, H., ZHANG, G., WU, J.-H., & JIANG, C.-P. (2014) · Oncology Reports · doi:10.3892/or.2014.3036 · Cited by 202
Parekh, V. V., Lalani, S., Kim, S., Halder, R., Azuma, M., Yagita, H., Kumar, V., Wu, L., & Van Kaer, L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803648 · Cited by 197
Harris, D. P., Goodrich, S., Gerth, A. J., Peng, S. L., & Lund, F. E. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.6781 · Cited by 191
Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy
Li, J., Wang, W., Zhang, Y., Cieślik, M., Guo, J., Tan, M., Green, M. D., Wang, W., Lin, H., Li, W., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134402 · Cited by 191
Cytokine Secretion Is Distinct from Secretion of Cytotoxic Granules in NK Cells
Reefman, E., Kay, J. G., Wood, S. M., Offenhäuser, C., Brown, D. L., Roy, S., Stanley, A. C., Low, P. C., Manderson, A. P., & Stow, J. L. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0803954 · Cited by 187
Naka, T., Tsutsui, H., Fujimoto, M., Kawazoe, Y., Kohzaki, H., Morita, Y., Nakagawa, Narazaki, M., Adachi, K., Yoshimoto, T., et al. (2001) · Immunity · doi:10.1016/s1074-7613(01)00132-7 · Cited by 186
Distribution of interferon‐γ receptor in human tissues
Valente, G., Ozmen, L., Novelli, F., Geuna, M., Palestro, G., Forni, G., & Garotta, G. (1992) · European Journal of Immunology · doi:10.1002/eji.1830220933 · Cited by 176
Single dose of anti–CTLA-4 enhances CD8 + T-cell memory formation, function, and maintenance
Pedicord, V. A., Montalvo, W., Leiner, I. M., & Allison, J. P. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016791108 · Cited by 174
Melén, K., Fagerlund, R., Franke, J., Köhler, M., Kinnunen, L., & Julkunen, I. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303571200 · Cited by 174
Current prospects of type II interferon γ signaling and autoimmunity
Green, D. S., Young, H. A., & Valencia, J. C. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.774745 · Cited by 172
Strauss, J., Heery, C. R., Kim, J. W., Jochems, C., Donahue, R. N., Montgomery, A. S., McMahon, S., Lamping, E., Marté, J. L., Madan, R. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1512 · Cited by 171
Qiang, L., Banks, A. S., & Accili, D. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.140228 · Cited by 168
Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy
Wolf, B. J., Choi, J. E., & Exley, M. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00384 · Cited by 166
IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin
Lane, R. S., Femel, J., Breazeale, A. P., Loo, C. P., Thibault, G., Kaempf, A., Mori, M., Tsujikawa, T., Chang, Y. H., & Lund, A. W. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180654 · Cited by 165
New predictors for immunotherapy responses sharpen our view of the tumour microenvironment
Bruno, T. C. (2020) · Nature · doi:10.1038/d41586-019-03943-0 · Cited by 165
Wu, S.-P., Liao, R.-Q., Tu, H., Wang, W., Dong, Z., Huang, S., Guo, W., Gou, L.-Y., Sun, H., Zhang, Q., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.11.132 · Cited by 163
Halim, L., Romano, M., McGregor, R., Correa, I., Pavlidis, P., Grageda, N., Hoong, S.-J., Yuksel, M., Jassem, W., Hannen, R. F., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.079 · Cited by 161
Long-distance modulation of bystander tumor cells by CD8+ T-cell-secreted IFN-γ
Hoekstra, M. E., Bornes, L., Dijkgraaf, F. E., Philips, D., Pardieck, I. N., Toebes, M., Thommen, D. S., van Rheenen, J., & Schumacher, T. N. (2020) · Nature Cancer · doi:10.1038/s43018-020-0036-4 · Cited by 160
Thibaut, R., Bost, P., Milo, I., Cazaux, M., Lemaître, F., Garcia, Z., Amit, I., Breart, B., Cornuot, C., Schwikowski, B., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0038-2 · Cited by 160
Wu, C., Xue, Y., Wang, P., Lin, L., Liu, Q., Li, N., Xu, J., & Cao, X. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302379 · Cited by 156
A comprehensive pathway map of IL-18-mediated signalling
Balaya, R. D. A., Agarwal, N., Prasad, T. S. K., Kandasamy, R. K., Subbannayya, Y., & Pinto, S. M. (2019) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-019-00544-4 · Cited by 156
Charych, D. H., Khalili, S., Dixit, V., Kirk, P. B., Chang, T., Langowski, J. L., Rubas, W., Doberstein, S. K., Eldon, M. A., Hoch, U., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179431 · Cited by 155
Structure of the IFNγ receptor complex guides design of biased agonists
Mendoza, J. L., Escalante, N. K., Jude, K. M., Bellón, J. S., Su, L., Horton, T. M., Tsutsumi, N., Berardinelli, S. J., Haltiwanger, R. S., Piehler, J., et al. (2019) · Nature · doi:10.1038/s41586-019-0988-7 · Cited by 150
Comprehensive network map of interferon gamma signaling
Bhat, M. Y., Solanki, H. S., Advani, J., Khan, A. A., Prasad, T. S. K., Gowda, H., Thiyagarajan, S., & Chatterjee, A. (2018) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-018-0486-y · Cited by 147
TIGIT signaling restores suppressor function of Th1 Tregs
Lucca, L. E., Axisa, P., Singer, E. R., Nolan, N. M., Dominguez‐Villar, M., & Hafler, D. A. (2019) · JCI Insight · doi:10.1172/jci.insight.124427 · Cited by 145
Regulation of interferon-γ gene expression by nuclear factor of activated T cells
Kiani, A., Garcia-Cozar, F. J., Habermann, I., Laforsch, S., Aebischer, T., Ehninger, G., & Rao, A. (2001) · Blood · doi:10.1182/blood.v98.5.1480 · Cited by 144
Interferon-γ is an autocrine mediator for dendritic cell maturation
Pan, J., Zhang, M., Wang, J., Wang, Q., Xia, D., Sun, W., Zhang, L., Yu, H. C., Liu, Y.-J., & Cao, X. (2004) · Immunology Letters · doi:10.1016/j.imlet.2004.05.003 · Cited by 144
Secondary T cell–T cell synaptic interactions drive the differentiation of protective CD8+ T cells
Gérard, A., Khan, O., Beemiller, P., Oswald, E. M., Hu, J. K., Matloubian, M., & Krummel, M. F. (2013) · Nature Immunology · doi:10.1038/ni.2547 · Cited by 144
An intrinsic role of IL-33 in Treg cell–mediated tumor immunoevasion
Hatzioannou, A., Banos, A., Sakellaropoulos, T., Fedonidis, C., Vidali, M.-S., Köhne, M., Händler, K., Boon, L., Henriques, A. R., Koliaraki, V., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0555-2 · Cited by 142
Pai, C.-C. S., Huang, J. T., Lu, X., Simons, D. M., Park, C., Chang, A., Tamaki, W., Liu, E., Roybal, K. T., Seagal, J., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.006 · Cited by 141
Stabilization of IFN-γ mRNA by MAPK p38 in IL-12– and IL-18–stimulated human NK cells
Mavropoulos, Α., Sully, G., Cope, A. P., & Clark, A. R. (2004) · Blood · doi:10.1182/blood-2004-07-2782 · Cited by 139
Evolutionarily conserved sequence elements that positively regulate IFN-γ expression in T cells
Shnyreva, M., Weaver, W. M., Blanchette, M., Taylor, S. L., Tompa, M., Fitzpatrick, D. R., & Wilson, C. B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400849101 · Cited by 138
Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70
Zobywalski, A., Javorovic, M., Frankenberger, B., Pohla, H., Kremmer, E., Bigalke, I., & Schendel, D. J. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-18 · Cited by 134
Lethality of interferon preparations for newborn mice
Gresser, I., Tovey, M. G., Maury, C., & CHOUROULINKOV, I. (1975) · Nature · doi:10.1038/258076a0 · Cited by 131
Interleukin-35: Expanding Its Job Profile
Sawant, D. V., Hamilton, K., & Vignali, D. A. A. (2015) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2015.0015 · Cited by 121
Self-citationPrimary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A. K., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · eScholarship (California Digital Library) · Cited by 120
Leukotrienes: positive signals for regulation of gamma-interferon production.
Johnson, H. M., & Torres, B. A. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.132.1.413 · Cited by 118
Regulation of IFN-γ Signaling Is Essential for the Cytotoxic Activity of CD8+ T Cells
Tau, G. Z., Cowan, S., Weisburg, J. H., Braunstein, N. S., & Rothman, P. B. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.10.5574 · Cited by 116
Chevolet, I., Speeckaert, R., Schreuer, M. S., Neyns, B., Krysko, O., Bachert, C., Hennart, B., Allorge, D., van Geel, N., Gele, M. V., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.982382 · Cited by 113
Liu, Z., Ravindranathan, R., Li, J., Kalinski, P., Guo, Z. S., & Bartlett, D. L. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1091554 · Cited by 113
Razaghi, A., Owens, L., & Heimann, K. (2016) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2016.10.022 · Cited by 102
The role of tumour-derived iNOS in tumour progression and angiogenesis
Kostourou, V., Cartwright, J. E., Johnstone, A. P., Boult, J. K. R., Cullis, E. R., Whitley, G. S. J., & Robinson, S. P. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6606034 · Cited by 101
Oncolytic vesicular stomatitis virus expressing interferon-σ has enhanced therapeutic activity
Bourgeois‐Daigneault, M., Roy, D. G., Falls, T. J., Twumasi‐Boateng, K., St-Germain, L. E., Marguerie, M., Garcia, V., Selman, M., Jennings, V. A., Pettigrew, J. L., et al. (2016) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2016.1 · Cited by 99
Biased signaling pathways via CXCR3 control the development and function of CD4+ T cell subsets
Karin, N., Wildbaum, G., & Thelen, M. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.2mr0915-441r · Cited by 97
New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5)
Piechutta, M., & Berghoff, A. S. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000510 · Cited by 96
Qing, Y., Costa‐Pereira, A. P., Watling, D., & Stark, G. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409863200 · Cited by 92
IDO1 is an Integral Mediator of Inflammatory Neovascularization
Mondal, A., Smith, C., DuHadaway, J. B., Sutanto‐Ward, E., Prendergast, G. C., Bravo‐Nuevo, A., & Muller, A. J. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.11.013 · Cited by 92
Zampell, J. C., Avraham, T., Yoder, N. D., Fort, N. M., Yan, A., Weitman, E. S., & Mehrara, B. J. (2011) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00306.2011 · Cited by 90
Yuba, E., Kanda, Y., Yoshizaki, Y., Teranishi, R., Harada, A., Sugiura, K., Izawa, T., Yamate, J., Sakaguchi, N., Koiwai, K., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.07.031 · Cited by 88
Stephens, J. M., Lumpkin, S. J., & Fishman, J. B. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.47.31408 · Cited by 86
Ameri, A. H., Tuchayi, S. M., Zaalberg, A., Park, J. H., Ngo, K. H., Li, T., Lopez, E., Colonna, M., Lee, R. T., Mino-Kenudson, M. A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815016116 · Cited by 85
PD-1 signaling modulates interferon-γ production by Gamma Delta (γδ) T-Cells in response to leukemia
Hoeres, T., Holzmann, E., Smetak, M., Birkmann, J., & Wilhelm, M. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1550618 · Cited by 82
Metzger, D. W., McNutt, R. M., Collins, J. T., Buchanan, J. M., Cleave, V. H. V., & Dunnick, W. A. (1997) · European Journal of Immunology · doi:10.1002/eji.1830270820 · Cited by 81
α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials
Zhang, Y., Springfield, R., Chen, S., Li, X., Feng, X., Moshirian, R., Yang, R., & Yuan, W. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01126 · Cited by 81
Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade
Chuang, Y.-C., Tseng, J., Huang, L.-R., Huang, C., Huang, C. F., & Chuang, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01075 · Cited by 79
Treg stability: to be or not to be
Overacre, A. E., & Vignali, D. A. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.009 · Cited by 78
Self-citationLarkin, J., Johnson, H. M., & Subramaniam, P. S. (2000) · Journal of Interferon & Cytokine Research · doi:10.1089/10799900050044769 · Cited by 76
A high-throughput assay of NK cell activity in whole blood and its clinical application
Lee, S.-B., Cha, J., Kim, I.-K., Yoon, J. C., Lee, H. J., Park, S. W., Cho, S., Youn, D., Lee, H., Lee, C. H., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.02.040 · Cited by 76
Hodge, D. L., Martínez, A., Julias, J. G., Taylor, L. S., & Young, H. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.6.1742-1753.2002 · Cited by 76
B cells and their cytokine activities implications in human diseases
Fillatreau, S. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.07.020 · Cited by 76
Evidence for a regulatory loop between IFN‐γ and IL‐33 in skin inflammation
Seltmann, J., Werfel, T., & Wittmann, M. (2012) · Experimental Dermatology · doi:10.1111/exd.12076 · Cited by 74
Kalathil, S. G., Hutson, A. D., Barbi, J. J., Iyer, R. V., & Thanavala, Y. M. (2019) · JCI Insight · doi:10.1172/jci.insight.130116 · Cited by 72
Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy
Zhang, H., Tang, W.-L., Kheirolomoom, A., Fite, B. Z., Wu, B., Lau, K. H., Baikoghli, M., Raie, M. N., Tumbale, S. K., Foiret, J. L., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.013 · Cited by 72
TNFα Augments Cytokine-Induced NK Cell IFNγ Production through TNFR2
Almishri, W., Santodomingo-Garzón, T., Le, T. S., Stack, D., Mody, C. H., & Swain, M. G. (2016) · Journal of Innate Immunity · doi:10.1159/000448077 · Cited by 71
IFN‐γ enhances TRAIL‐induced apoptosis through IRF‐1
Park, S., Seol, J., Lee, Y., Cho, J., Kang, H., Kim, I., Park, S., Kim, T., Yim, J. H., Kim, M., et al. (2004) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.2004.04362.x · Cited by 70
Th1 cytokine-based immunotherapy for cancer
Xu, H. (2014) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(14)60305-2 · Cited by 70
Oh, E., Choi, I., Hong, J., & Yun, C. (2016) · Oncotarget · doi:10.18632/oncotarget.13972 · Cited by 70
Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy
Vitale, L. A., Thomas, L. J., He, L.-Z., O’Neill, T. J., Widger, J., Crocker, A., Sundarapandiyan, K., Storey, J. R., Forsberg, E. M., Weidlick, J., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2267-0 · Cited by 69
Sun, T., Yang, Y., Luo, X., Cheng, Y. Z., Zhang, M., Wang, K., & Ge, C. (2014) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504014x13890370410285 · Cited by 66
Wang, H., Zhang, Y., Wu, X., Wang, Y., Cui, H., Li, X., Zhang, J., Tun, N., Peng, Y., & Yu, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00293 · Cited by 66
The dual role of mir-146a in metastasis and disease progression
Alipour, S., Shiva, G. G.-A., Babaei, G., Jeddi, F., Hosein, A., & Parsa, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110099 · Cited by 66
Li, J., Yang, Y., Inoue, H., Mori, M., & Akiyoshi, T. (1996) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050324 · Cited by 62
Madonna, S., Scarponi, C., Sestito, R., Pallotta, S., Cavani, A., & Albanesi, C. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001426 · Cited by 60
Lee, J., Park, K. H., Ryu, J. H., Bae, H. J., Choi, A., Lee, H., Lim, J., Han, K., Park, C. H., Jung, E. S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19712 · Cited by 60
Rakshit, S., Subramanian, B. C., Saha, B., Victor, E. S., Majumdar, S., & Nandi, D. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.06.014 · Cited by 59
Henriksen, J. R., Donskov, F. N., Waldstrøm, M., Jakobsen, A. K. M., Hjortkjær, M., Petersen, C. B., & Steffensen, K. D. (2020) · Acta Oncologica · doi:10.1080/0284186x.2019.1711173 · Cited by 56
Moreno, M., Molling, J. W., von Mensdorff‐Pouilly, S., Verheijen, R. H. M., Hooijberg, E., Kramer, D., Reurs, A. W., van den Eertwegh, A. J. M., Blomberg, B. M. E. V., Scheper, R. J., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.4.2446 · Cited by 55
Soutto, M., Zhou, W., & Aune, T. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.12.6664 · Cited by 51
Mauldin, I. S., Wages, N. A., Stowman, A. M., Wang, E., Smolkin, M. E., Olson, W. C., Deacon, D. H., Smith, K. T., Galeassi, N., Chianese‐Bullock, K. A., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1881-y · Cited by 51
Oyler, J. E., Oyler‐Yaniv, A., Shakiba, M., Min, N., Chen, Y.-H., Cheng, S.-Y., Krichevsky, O., Altan‐Bonnet, N., & Altan-Bonnet, G. Y. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.05.011 · Cited by 49
Tumor Regression and Cure Depends on Sustained Th1 Responses
Dai, M., Hellström, I., Yip, Y. Y., Sjögren, H. O., & Hellström, K. E. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000231 · Cited by 45
Second messenger role of arachidonic acid and its metabolites in interferon-gamma production.
Johnson, H. M., Russell, J. K., & Torres, B. A. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.137.10.3053 · Cited by 40
Stoycheva, D., Deiser, K., Stärck, L., Nishanth, G., Schlüter, D., Uckert, W., & Schüler, T. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1402058 · Cited by 40
Liang, Y., Jie, Z., Hou, L., Yi, P., Wang, W., Kwota, Z., Salvato, M. S., Malefyt, R. D. W., Soong, L., & Sun, J. (2015) · European Journal of Immunology · doi:10.1002/eji.201545696 · Cited by 38
Das, R., Bassiri, H., Guan, P. F., Wiener, S. J., Banerjee, P. P., Zhong, M., Veillette, A., Orange, J. S., & Nichols, K. E. (2013) · Blood · doi:10.1182/blood-2012-11-468868 · Cited by 36
Takami, M., Ihara, F., & Motohashi, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02021 · Cited by 36
A mechanism underlying STAT4-mediated up-regulation of IFN- induction inTCR-triggered T cells
Park, W.-R. (2004) · International Immunology · doi:10.1093/intimm/dxh034 · Cited by 34
Hemmerle, T., & Neri, D. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0182 · Cited by 33
Elucidating the crosstalk mechanism between IFN-gamma and IL-6 via mathematical modelling
Qi, Y.-F., Huang, Y., Wang, H., Zhang, Y., Bao, Y., Sun, L., Wu, Y., Yu, C., Song, Z., Zheng, L., et al. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-41 · Cited by 30
Prabhu, N., Ho, A. W. S., Wong, K. H. S., Hutchinson, P. E., Chua, Y. L., Kandasamy, M., Lee, D. C. P., Sivasankar, B., & Kemeny, D. M. (2013) · Journal of Virology · doi:10.1128/jvi.01776-13 · Cited by 29
Miyakawa, N., Nishikawa, M., Takahashi, Y., Ando, M., Misaka, M., Watanabe, Y., & Takakura, Y. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22473 · Cited by 28
Watcharanurak, K., Zang, L., Nishikawa, M., Yoshinaga, K., Yamamoto, Y., Takahashi, Y., Ando, M., Saito, K., Watanabe, Y., & Takakura, Y. (2014) · Gene Therapy · doi:10.1038/gt.2014.54 · Cited by 28
Sadlik, J. R., Hoyer, M., Leyko, M. A., Horvat, R. T., Parmely, M. J., Whitacre, C. C., Zwilling, B. S., & Rinehart, J. J. (1985) · PubMed · Cited by 22
Holzer, U., Reinhardt, K., Lang, P., Handgretinger, R., & Fischer, N. (2013) · Human Immunology · doi:10.1016/j.humimm.2013.02.002 · Cited by 19
Ando, M., Takahashi, Y., Yamashita, T., Fujimoto, M., Nishikawa, M., Watanabe, Y., & Takakura, Y. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.23 · Cited by 18
Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity
Putz, E. M., Majoros, A., Gotthardt, D., Prchal‐Murphy, M., Zebedin-Brandl, E. M., Fux, D. A., Schlattl, A., Schreiber, R. D., Carotta, S., Müller, M. M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1186314 · Cited by 18
Ma, N., Wei, T., Wang, B., Jiang, X., Zhou, L., & Zhong, R. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.10.85 · Cited by 13
Maio, M., Coukos, G., Ferrone, S., Fox, B. A., Fridman, W. H., Garcia, P. L., Lahn, M., Provendier, O., Russo, V., Rüttinger, D., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2285-y · Cited by 12
Cited by
Immune Checkpoint Inhibitors in Cancer Therapy
Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353
Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies
Zhou, Q., Meng, Y., Li, D., Yao, L., Le, J., Liu, Y., Sun, Y., Zeng, F., Chen, X., & Deng, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01769-5 · Cited by 890
Speiser, D. E., Chijioke, O., Schaeuble, K., & Münz, C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00521-2 · Cited by 479
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
Spatial CRISPR genomics identifies regulators of the tumor microenvironment
Dhainaut, M., Rose, S. A., Akturk, G., Wroblewska, A., Nielsen, S. R., Park, E. S., Buckup, M., Roudko, V., Pia, L., Sweeney, R., et al. (2022) · Cell · doi:10.1016/j.cell.2022.02.015 · Cited by 281
Metadata
- Authors
- Gocher, A. M., Workman, C. J., & Vignali, D. A. A.
- Venue
- Nature Reviews Immunology
- Published
- 2021-06-21
- Volume
- 22
- Issue
- 3
- Pages
- 158-172
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W3176649308
- Cited by
- 582
- References
- 195
- FWCI
- 14.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.